We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Other disorders of the nervous systemMalignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This study is designed to investigate immune responses and inflammation in neurological diseases and cancer by enabling a unique multidisciplinary approach. The nervous system and cancer share an interesting property called "immune privilege", an umbrella term for different mechanisms preventing immune responses. When this immune privilege breaks down in the nervous system, neurological disease occurs. In contrast breakdown of immune privilege in cancer is desirable to allow immune attack and enable immunotherapy. In rare cases, immune responses targeted against both nervous system and cancer result in paraneoplastic neurological disease. This study aims to understand these links to improve the prevention, diagnosis and treatment of neurological diseases and cancer. This will be facilitated by bringing experts from both fields working together.
Anonymized clinical details and samples from patients with neurological disease, cancer, or both, will be collected by the chief investigator and his collaborators. The opportunity to study immune responses against nervous system and cancer antigens in the same clinical cases will provide new insights into disease mechanism and treatment for patients with both conditions. Since some neurological conditions are rare, nationwide recruitment will be needed via collaborative clinical networks already in place. Clinical samples will be collected as additional blood samples or from excess diagnostic samples during routine management of patients. Samples may include whole blood, white blood cells, plasma, serum, biopsies, urine, aspirates, washings and cerebrospinal fluid; they will be stored by the University of Southampton Cancer Sciences Division Tissue Bank. Samples will be analysed using immunological, histological, genetic, molecular, chemical and physical techniques. A very important aspect of the study is indefinite storage of samples to allow re-analysis of archival material and in order to test hypotheses or diagnose
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
For additional blood samples: haemoglobin <11 g/dl significant bleeding tendency
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST and funded by ACADEMY OF MEDICAL SCIENCES; CANCER RESEARCH UK; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 10925
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
